INDV
Indivior Pharmaceuticals, Inc. · Healthcare · Market cap $4.1B
Insiders sold $2.7M net in the last 90 days ·2 sellers, 1 buyer· 3 of 3 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 27, 2026
Insider Buying
$312K
reported purchases (SEC code P)
Insider Selling
$2.8M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Aug 27, 2026
Anderson Woodrow D
Indivior Pharmaceuticals, Inc. (INDV) has 39 SEC Form 4 filings (48 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 27, 2026.
Inside the rolling window, 9 insiders at Indivior Pharmaceuticals, Inc. reported 10 open-market purchases totaling $312K and 3 open-market sales totaling $2.8M. The most active filer is Director Ryan Barbara with 3 filings. Insiders have net sold $2.7M over the trailing 6 months. The most recent open-market filing is a purchase of 1,500 shares by Chief Accounting Officer Anderson Woodrow D, dated Aug 27, 2026, worth $54K.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Joseph J. Ciaffoni
- Employees:833
- HQ:North Chesterfield, VA, US
- IPO:2014-12-29
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Accounting Officer | Purchase | 1,500 | $54K | Aug 27 | -2.3% | SEC ↗ | |
Anderson Woodrow DFirst filing | Chief Accounting Officer | Purchase | 1,500 | $54K | Aug 5 | -10.9% | SEC ↗ |
| Chief Scientific Officer | Sale | 18,586 | $765K | Jul 13 | -14.2% | SEC ↗ | |
Heidbreder ChristianFirst filing | Chief Scientific Officer | Sale | 18,586 | $707K | Jun 12 | -10.4% | SEC ↗ |
Preblick RyanFirst filing | Chief Financial Officer | Sale | 36,000 | $1.4M | Jun 10 | -9.5% | SEC ↗ |
| Director | Purchase | 8 | $249 | Mar 13 | +10.9% | SEC ↗ | |
Kingsley Stuart AFirst filing | Director | Purchase | 940 | $30K | Mar 11 | +5.1% | SEC ↗ |
| Director | Purchase | 31 | $1K | Mar 11 | +5.1% | SEC ↗ | |
Ryan BarbaraFirst filing | Director | Purchase | 775 | $27K | Jan 7 | -3.9% | SEC ↗ |
NINIVAGGI DANIEL AFirst filing | Director | Purchase | 775 | $27K | Jan 7 | -3.9% | SEC ↗ |
Wheadon David E.First filing | Director | Purchase | 1,771 | $63K | Jan 7 | — | SEC ↗ |
Humphreys KeithFirst filing | Director | Purchase | 775 | $27K | Jan 7 | — | SEC ↗ |
Stejbach MarkFirst filing | Director | Purchase | 775 | $27K | Jan 7 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does INDV have?
Indivior Pharmaceuticals, Inc. (INDV) has 39 SEC Form 4 filings (48 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Aug 27, 2026.
When was the most recent SEC Form 4 filing for INDV?
The most recent Form 4 filing for INDV on Tracefour is dated Aug 27, 2026.
Who is the most active insider at INDV?
The most active SEC Form 4 filer at INDV in the rolling window is Director Ryan Barbara, with 3 filings.
What is the net insider flow at INDV over the last 6 months?
Over the trailing 180 days, insiders at INDV have net sold $2.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at INDV in the current window?
Inside the rolling window, insiders at INDV bought $312K and sold $2.8M based on SEC Form 4 filings.
Can I get alerts for INDV insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Indivior Pharmaceuticals, Inc. (INDV). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Indivior Pharmaceuticals, Inc. is in the Healthcare sector.